Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edesa Biotech, Inc.EDSA · Entity 7223 | Director | March 28, 2022 | March 30, 2022 |
| Endo International plcENDP · Entity 124463 | Director | June 11, 2021 | June 15, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edesa Biotech, Inc.
Report date March 28, 2022 · Filed March 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2032-03-28 | Direct | 30,000 |
Reported balance
After 2022-03-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-28 · Grant · Acquired 30,000 · Balance 30,000 F1: This option vests monthly in equal proportions over 12 months beginning on the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests monthly in equal proportions over 12 months beginning on the Grant Date.
Endo International plc
Report date June 11, 2021 · Filed June 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 24,921 |
Ending reported balance
After 2021-06-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-06-11 · Grant · Acquired 47,924 · Balance 47,924 F1: These ordinary shares were granted to Ms. Chao on June 11, 2021 in consideration of her services on Endo International plc's Board of Directors. Row 2 · 2021-06-11 · Tax withholding · Disposed 23,003 · Balance 24,921 F2: These shares represent ordinary shares withheld by Endo International plc to satisfy Ms. Chao's tax withholding obligations on shares acquired on June 11, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: These ordinary shares were granted to Ms. Chao on June 11, 2021 in consideration of her services on Endo International plc's Board of Directors.
F2: These shares represent ordinary shares withheld by Endo International plc to satisfy Ms. Chao's tax withholding obligations on shares acquired on June 11, 2021.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOSPECIFICS TECHNOLOGIES CORP
Report date December 02, 2020 · Filed December 02, 2020
Section 16 reporting ended · disclosed 2020-12-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-12-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-12-02 · Disposition to issuer · Disposed 1,920 · Balance 1,726 F1: Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020 (the "Merger Agreement"), 1,920 shares of common stock were exchanged for a cash payment of $169,920.00, representing the product obtained by multiplying the offer price ($88.50) by the number of shares owned by the reporting person. Row 2 · 2020-12-02 · Disposition to issuer · Disposed 1,726 · Balance 0 F2: Upon the consummation of the Merger, pursuant to the Merger Agreement, 1,726 outstanding restricted stock units ("RSUs") were canceled in exchange for a cash payment of $152,751.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the RSUs, by (y) the offer price ($88.50). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.64 · Expires 2025-04-22 | Direct | 20,000 |
Reported balance
After 2020-12-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-02 · Disposition to issuer · Disposed 1,687 · Balance 20,000 F3: Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which provided for vesting in four equal annual installments following the grant date (April 22, 2015), were canceled in exchange for a cash payment of $85,800.82, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.82 · Expires 2028-03-15 | Direct | 5,000 |
Reported balance
After 2020-12-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-02 · Disposition to issuer · Disposed 15,000 · Balance 5,000 F4: Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which provided for vesting in four equal annual installments following the grant date (March 15, 2018), were canceled in exchange for a cash payment of $700,200.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.62 · Expires 2030-03-13 | Direct | 0 |
Reported balance
After 2020-12-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-02 · Disposition to issuer · Disposed 5,000 · Balance 0 F5: Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which would have vested in full on the one-year anniversary of the grant date (March 13, 2020), were canceled in exchange for a cash payment of $164,400.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020 (the "Merger Agreement"), 1,920 shares of common stock were exchanged for a cash payment of $169,920.00, representing the product obtained by multiplying the offer price ($88.50) by the number of shares owned by the reporting person.
F2: Upon the consummation of the Merger, pursuant to the Merger Agreement, 1,726 outstanding restricted stock units ("RSUs") were canceled in exchange for a cash payment of $152,751.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the RSUs, by (y) the offer price ($88.50).
F3: Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which provided for vesting in four equal annual installments following the grant date (April 22, 2015), were canceled in exchange for a cash payment of $85,800.82, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option.
F4: Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which provided for vesting in four equal annual installments following the grant date (March 15, 2018), were canceled in exchange for a cash payment of $700,200.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option.
F5: Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which would have vested in full on the one-year anniversary of the grant date (March 13, 2020), were canceled in exchange for a cash payment of $164,400.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 28, 2022 Filed Mar 30, 2022 22:52 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001654954-22-004197 · section16.xml · derivative · entry 1 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2032-03-28 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the Grant Date. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:09 UTC | Endo International plc ENDP · Entity 124463 | Tax withholdingOrdinary Shares | 23,003 | $6.26 | $143,998.78 |
DisclosureSEC source: 0001593034-21-000081 · wf-form4_162378771869931.xml · nonDerivative · entry 2 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,921 F2 · kind: These shares represent ordinary shares withheld by Endo International plc to satisfy Ms. Chao's tax withholding obligations on shares acquired on June 11, 2021. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:09 UTC | Endo International plc ENDP · Entity 124463 | GrantOrdinary Shares | 47,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001593034-21-000081 · wf-form4_162378771869931.xml · nonDerivative · entry 1 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,924 F1 · kind: These ordinary shares were granted to Ms. Chao on June 11, 2021 in consideration of her services on Endo International plc's Board of Directors. Read SEC document |
| December 02, 2020 Filed Dec 2, 2020 09:48 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,000 | $32.88 Strike: $55.62 | $164,400.00 |
DisclosureSEC source: 0000899243-20-032458 · doc4.xml · derivative · entry 5 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2030-03-13 F5 · derivative.exercise_date: Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which would have vested in full on the one-year anniversary of the grant date (March 13, 2020), were canceled in exchange for a cash payment of $164,400.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option. Read SEC document |
| December 02, 2020 Filed Dec 2, 2020 09:48 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | $46.68 Strike: $41.82 | $700,200.00 |
DisclosureSEC source: 0000899243-20-032458 · doc4.xml · derivative · entry 4 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 15,000 shares Expires 2028-03-15 F4 · derivative.exercise_date: Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which provided for vesting in four equal annual installments following the grant date (March 15, 2018), were canceled in exchange for a cash payment of $700,200.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option. Read SEC document |
| December 02, 2020 Filed Dec 2, 2020 09:48 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,687 | $50.86 Strike: $37.64 | $85,800.82 |
DisclosureSEC source: 0000899243-20-032458 · doc4.xml · derivative · entry 3 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 1,687 shares Expires 2025-04-22 F3 · derivative.exercise_date: Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which provided for vesting in four equal annual installments following the grant date (April 22, 2015), were canceled in exchange for a cash payment of $85,800.82, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option. Read SEC document |
| December 02, 2020 Filed Dec 2, 2020 09:48 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | Disposition to issuerCommon Stock, $0.001 par value | 1,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-032458 · doc4.xml · nonDerivative · entry 2 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Upon the consummation of the Merger, pursuant to the Merger Agreement, 1,726 outstanding restricted stock units ("RSUs") were canceled in exchange for a cash payment of $152,751.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the RSUs, by (y) the offer price ($88.50). Read SEC document |
| December 02, 2020 Filed Dec 2, 2020 09:48 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | Disposition to issuerCommon Stock, $0.001 par value | 1,920 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-032458 · doc4.xml · nonDerivative · entry 1 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,726 F1 · price: Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020 (the "Merger Agreement"), 1,920 shares of common stock were exchanged for a cash payment of $169,920.00, representing the product obtained by multiplying the offer price ($88.50) by the number of shares owned by the reporting person. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 17:52 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | GrantCommon Stock, $0.001 par value | 1,726 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019548 · doc4.xml · nonDerivative · entry 1 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,646 F1 · kind: Grant of restricted stock units under the BioSpecifics Technologies Corp. 2019 Omnibus Incentive Compensation Plan. The restricted stock units generally will vest in full on the first anniversary of the date of grant. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 17:06 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $55.62 | $0.00 |
DisclosureSEC source: 0001062993-20-001377 · form4.xml · derivative · entry 1 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2020-03-13 F1 · kind: The stock options were granted under the BioSpecifics Technologies Corp. 2019 Omnibus Incentive Compensation Plan. F2 · derivative.exercise_date: The stock options vest ratably over the one-year period following the date of grant, March 13, 2020. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 09:30 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | GrantCommon Stock, $0.001 par value | 1,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-19-002792 · form4.xml · nonDerivative · entry 1 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,920 F1 · kind: Grant of restricted stock units under the BioSpecifics Technologies Corp. 2019 Omnibus Incentive Compensation Plan. Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 18:18 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | SaleCommon Stock, $0.001 par value | 459 | $58.55 | $26,874.45 |
DisclosureSEC source: 0001062993-19-002567 · form4.xml · nonDerivative · entry 1 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30 Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 16:45 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | SaleCommon Stock, $0.001 par value | 500 | $57.25 | $28,625.00 |
DisclosureSEC source: 0001062993-19-002531 · form4.xml · nonDerivative · entry 3 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489 Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 16:45 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | SaleCommon Stock, $0.001 par value | 2,411 | $58.01 | $139,862.11 |
DisclosureSEC source: 0001062993-19-002531 · form4.xml · nonDerivative · entry 2 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 989 F2 · price: The selling price of $58.01 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $57.80 to $58.60. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 16:45 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | SaleCommon Stock, $0.001 par value | 2,600 | $56.56 | $147,056.00 |
DisclosureSEC source: 0001062993-19-002531 · form4.xml · nonDerivative · entry 1 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,400 F1 · price: The selling price of $56.56 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $56.50 to $56.60. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 29, 2019 Filed Jun 3, 2019 11:00 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | SaleCommon Stock, $0.001 par value | 3,313 | $60.74 | $201,231.62 |
DisclosureSEC source: 0001062993-19-002495 · form4.xml · nonDerivative · entry 1 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · price: The selling price of $60.74 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $60.70 to $60.755. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 22, 2019 Filed May 23, 2019 17:34 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $37.64 | $0.00 |
DisclosureSEC source: 0001062993-19-002396 · form4.xml · derivative · entry 2 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,687 Underlying: Common Stock · 8,000 shares Expires 2025-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested in four equal annual installments beginning on the first anniversary of the date of grant (4/22/2015). Read SEC document |
| May 22, 2019 Filed May 23, 2019 17:34 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | Exercise / conversionCommon Stock, $0.001 par value | 8,000 | $37.64 | $301,120.00 |
DisclosureSEC source: 0001062993-19-002396 · form4.xml · nonDerivative · entry 1 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2019 Filed May 21, 2019 21:46 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | SaleCommon Stock, $0.001 par value | 2,000 | $64.00 | $128,000.00 |
DisclosureSEC source: 0001062993-19-002366 · form4.xml · nonDerivative · entry 2 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,313 Read SEC document |
| May 17, 2019 Filed May 21, 2019 21:46 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | SaleCommon Stock, $0.001 par value | 2,000 | $63.43 | $126,860.00 |
DisclosureSEC source: 0001062993-19-002366 · form4.xml · nonDerivative · entry 1 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,313 Read SEC document |
| May 16, 2019 Filed May 21, 2019 16:06 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | Exercise / conversionStock Option (right to buy) · Derivative | 5,313 | $0.00 Strike: $37.64 | $0.00 |
DisclosureSEC source: 0001062993-19-002362 · form4.xml · derivative · entry 2 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,313 shares Expires 2025-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested in four equal annual installments beginning on the first anniversary of the date of grant (4/22/2015). Read SEC document |
| May 16, 2019 Filed May 21, 2019 16:06 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | Exercise / conversionCommon Stock, $0.001 par value | 5,313 | $37.64 | $199,981.32 |
DisclosureSEC source: 0001062993-19-002362 · form4.xml · nonDerivative · entry 1 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 18:27 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $41.82 | $0.00 |
DisclosureSEC source: 0001062993-18-001263 · form4.xml · derivative · entry 1 Chao Jennifer M · CIK 0001639625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-03-15 F1 · derivative.exercise_date: The options were granted on March 15, 2018, and will vest in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.